Analysts Set Expectations for Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Investment analysts at Barrington Research issued their Q3 2025 earnings estimates for shares of Surmodics in a research report issued to clients and investors on Thursday, May 1st. Barrington Research analyst M. Petusky expects that the company will post earnings of ($0.21) per share for the quarter. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.57) EPS, Q1 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.09) EPS.

SRDX has been the topic of a number of other research reports. Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Wednesday, April 30th. Finally, StockNews.com assumed coverage on shares of Surmodics in a research note on Monday, February 3rd. They set a “hold” rating for the company. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $43.00.

Surmodics Stock Up 1.5 %

SRDX stock opened at $27.37 on Monday. Surmodics has a one year low of $26.00 and a one year high of $42.44. The firm has a market cap of $391.36 million, a PE ratio of -27.10 and a beta of 1.32. The firm’s 50 day moving average price is $29.13 and its 200-day moving average price is $34.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.07). Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. The firm had revenue of $28.09 million for the quarter, compared to analysts’ expectations of $32.23 million.

Institutional Investors Weigh In On Surmodics

Several institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. acquired a new position in Surmodics in the 3rd quarter valued at about $1,190,000. JPMorgan Chase & Co. boosted its stake in shares of Surmodics by 192.7% in the third quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company’s stock valued at $1,647,000 after purchasing an additional 27,960 shares during the period. Barclays PLC grew its holdings in shares of Surmodics by 16.0% in the third quarter. Barclays PLC now owns 88,750 shares of the company’s stock valued at $3,443,000 after purchasing an additional 12,271 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after purchasing an additional 1,255 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Surmodics by 165.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,000 shares of the company’s stock worth $1,188,000 after buying an additional 18,692 shares during the period. Hedge funds and other institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).